Gilead Sciences : Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
Message : Required fields – >98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks – Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy ® (bictegravir 50 mg/emtricita...
Source: marketscreener.com